Core Insights - The Chinese pharmaceutical industry is at a significant "structural turning point," involving a systemic reconstruction of technology, market dynamics, value logic, and global roles [1] - The trend of Chinese pharmaceutical companies increasingly engaging in overseas licensing agreements is notable, with a total of nearly $66 billion in licensing deals in the first half of 2025 [2][4] - China's innovation in pharmaceuticals is gaining global recognition, with a substantial increase in the number of approved innovative drugs and clinical trial registrations surpassing those in the U.S. for two consecutive years [4][5] Group 1 - Chinese pharmaceutical companies are transitioning from generic drugs to innovative drugs, focusing on original drugs with new mechanisms and targets, as evidenced by significant licensing agreements with global pharmaceutical giants [2][3] - The quality of Chinese pharmaceutical innovation is improving, with research and development speeds 30% to 40% faster than global benchmarks, while asset valuations remain lower at 60% to 70% of global levels [4][6] - The number of approved innovative drugs in China reached 43 in the first half of the year, marking a 59% increase year-on-year, alongside a 87% increase in innovative medical devices [5][6] Group 2 - Challenges remain in the industry, including low concentration, poor accessibility of new drugs, and insufficient original innovation, necessitating strategies like internationalization and industrial transformation [6] - The industry is still positioned at the lower end of the value chain, with calls for building international innovation platforms to capture a larger share of global innovation benefits [6] - The integration of basic research with industrial transformation is crucial for achieving a turning point in China's innovative drug sector, focusing on unmet clinical needs rather than competing in existing markets [6]

11月25日，在2025第十七届中国医药企业家科学家投资家大会(启思会)暨海淀医药健康全产业链创新峰 会上，中国医药企业管理协会宣布成立医药营销创新专业委员会(以下简称：专委会)，中国医药企业管 理协会执行会长吴海东、中国医药企业管理协会副会长谭勇出席，京东健康作为常务副主任委员单位参 与成立仪式。 近年来，京东健康深耕数字营销领域，构建更加融合开放的合作生态。经过长期的数字化营销实践，京 东健康沉淀了贯穿患者全周期、实现更精准、更高效的药品全域营销解决方案。今年10月，京东健康数 字营销方案实现升级，改变过去药企与不同渠道方对接的"多对多"复杂合作困境，打造"一对多"合作新 模式。药企只需与京东健康单一平台合作，即可借助其搭建的全渠道服务网络，轻松触达线上、线下多 类市场，大幅降低渠道拓展成本，提升生意运营效率。 未来，京东健康将依托专委会力量，加深与药企数字化营销合作，为医药资源可及、药企市场增量及医 药行业高质量发展提供强劲助力。 随着医药行业政策深化调整、患者需求升级与技术快速迭代，医药产业升级不仅依靠前沿技术进步，也 取决于研发、生产与营销的全链条协同创新。为响应国家高质量发展战略，中国医药企业管理 ...

泰州中国医药城 ◎记者 仲茜 严曦梦 梅郎故里、溱湖水乡，江苏泰州作为长江中下游重要内河港口，自古是鱼米之乡、江淮经济重镇，如今 更是长三角中轴城市、大上海都市圈重要成员。2009年5月，泰州医药高新技术产业开发区（又称"中国 医药城"）挂牌成立，是我国唯一的国家级医药高新区。 建在泰州的医药城，为何叫"中国医药城"？企业家为什么选择在中国医药城创业？近日，上海证券报记 者走进泰州，走进中国医药城，探寻企业成长之路，感知产业发展脉搏。 先发优势： 建科技"底座"，育研发"新苗" 2009年3月，国务院批复泰州医药高新技术产业开发区升级为国家级高新区，成为当时全国第一个以医 药健康产业定位命名的高新区。 "2008年，依托扬子江药业、济川药业等老牌药厂，泰州锚定生物医药产业，下先手棋，将该产业定为 全市的主导产业，快速开建医药产业园。"泰州生物医药产业园管理办党工委委员、副主任赵荣林向上 海证券报记者回忆说。 与上海、苏州主攻生物医药研发方向不同，泰州中国医药城以研发疫苗、抗体和体外诊断试剂及医疗器 械产业为突破口。成立之初，中国医药城便围绕主攻方向，设立园区公共试验平台、中试平台，构建科 技研发底座，花费五年 ...

Group 1: Market Overview - In the US and five European countries, innovative drugs account for 70%-80% of the local market, while in China, the market share of innovative drugs is only 8.6% [1][10] - The Chinese innovative drug market is experiencing a "structural turning point," which is expected to reverse the downward trend in the pharmaceutical industry [1] - The domestic pharmaceutical terminal sales are projected to show negative growth starting in 2024, with over 30% of regulated pharmaceutical companies reporting losses in the first half of this year [1][3] Group 2: Industry Challenges - The pharmaceutical industry is facing a survival crisis due to external growth factors diminishing, and the capital market's enthusiasm for business development (BD) transactions cooling down [3] - The low concentration in several sub-sectors, particularly in the generic drug industry, has led to price competition, which is a key constraint on the development of the Chinese pharmaceutical industry [3][4] - The average price level of generic drugs has been further reduced due to policies on price governance and drug price comparison [4] Group 3: Innovative Drug Growth - Despite the overall revenue decline in the pharmaceutical industry, innovative drug companies have maintained good growth and profitability, with some achieving record high revenues [1][7] - The market size of innovative drugs (including biosimilars) reached 120 billion yuan in 2023, with a growth rate of 27% [7] - The revenue growth rate for biological products was 2.2%, with profit growth at 10.6%, indicating a strong performance in the innovative drug sector [8][7] Group 4: Regulatory and Policy Developments - The National Healthcare Security Administration has announced reforms to improve the immediate settlement of medical insurance funds, which is expected to alleviate the financial pressure on hospitals and improve drug payment timelines [5][6] - The implementation of policies to expand the scope of drug procurement and price control is expected to further impact the market dynamics [4][10] Group 5: Future Opportunities - The commercial potential of innovative drugs is anticipated to become the core driver of industry growth during the downturn [7] - The increasing number of innovative drug approvals and the shift in hospital medication structure are expected to enhance the market share of innovative products [7] - The industry is encouraged to build international innovation platforms to capture a larger share of the global market [2][18]

Core Points - The Shanghai Composite Index is at 3868.16 points, slightly down by 0.05%, with total A-share trading volume at 1.4667 trillion yuan [1] - 100 A-shares have surpassed the half-year line today, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently above its half-year line, indicating a stable market performance [1] - The total trading volume of A-shares reached 1.4667 trillion yuan, reflecting active market participation [1] Notable Stocks - Stocks with the highest deviation rates from the half-year line include: - Yingjixin (688209) with a deviation rate of 9.77% and a price increase of 12.56% [1] - Fuyuan Pharmaceutical (601089) with a deviation rate of 9.66% and a price increase of 10.00% [1] - Meiyan Jixiang (600868) with a deviation rate of 9.62% and a price increase of 10.10% [1] - Other stocks with significant performance include: - Guangbai Co. (002187) with a 9.95% increase and a deviation rate of 8.80% [1] - Chitianhua (600227) with a 10.16% increase and a deviation rate of 8.44% [1] Additional Stocks - Other notable stocks with positive performance and deviation rates include: - Yuekang Pharmaceutical (688658) with a 10.88% increase and a deviation rate of 8.40% [1] - Haiwang Biological (000078) with a 10.20% increase and a deviation rate of 7.79% [1] - Stocks with lower deviation rates but still above the half-year line include: - Guizhou Maotai and China Medical with minor deviations, indicating a stable position [1]

Group 1 - The 17th China Pharmaceutical Entrepreneurs Scientists Investors Conference, themed "Structural Turning Point," was held from November 24 to 26, 2025, in Haidian District, Beijing [1] - The conference serves as a high-profile platform for value linkage in the Chinese pharmaceutical industry and is a key event of the "Intelligent Gathering Haidian" talent theme week [1] - The establishment of the "National Traditional Chinese Medicine Inheritance and Innovation Center" at Xiyuan Hospital was witnessed by national and municipal authorities during the conference [1] Group 2 - The Haidian District "Zhongguancun Science City Technology Growth Fund" has reached a total scale of 20 billion yuan across three phases, focusing on the pharmaceutical and health sectors [2] - The fund aims to expand its scale through collaboration with market-oriented investment institutions, creating a comprehensive investment matrix to support the entire pharmaceutical health industry chain [2] - Haidian District is committed to becoming an innovation hub and investment hotspot for the pharmaceutical health industry by integrating technological and industrial innovation [2]

证券代码：600056 证券简称：中国医药 公告编号：临2025-088号 中国医药健康产业股份有限公司第九届董事会第33次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第33次会议（以下简称"本次会 议"）于2025年11月24日以现场结合通讯方式召开，会议由董事长、总经理杨光先生主持，公司部分高 级管理人员列席了本次会议。 (二)本次会议通知于2025年11月19日以邮件、短信、电话或传真的方式向全体董事发出。 (三)本次会议应参加会议董事8名，实际参加会议董事8名。 (四)本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议为有效决议。 二、会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于修订〈内部审计工作规定〉的议案》。 制度全文请详见上海证券交易所网站（www.sse.com.cn）。 表决结果：同意8票；反对0票；弃权0票。 （二）审议通过了《关于制定〈董事会议案管理办法〉的议案》。 制 ...

中国医药健康产业股份有限公司 董事会议案管理办法 第一章 总则 第一条 为规范中国医药健康产业股份有限公司（以下简 称"公司"）董事会议案管理，提高董事会规范运作水平和 议事效率，加强决策的科学性，根据《中华人民共和国公司 法》《中华人民共和国证券法》等法律法规、规范性文件和 《中国医药健康产业股份有限公司章程》（以下简称"《公 司章程》"）《中国医药健康产业股份有限董事会议事规则》 （以下简称"《董事会议事规则》"）等规定，制定本办法。 第二条 本办法所称董事会议案，是指根据《公司章程》 《董事会议事规则》等有关规定提交董事会审议事项的正式 文件材料。 第三条 董事会议案的提议人主体，可通过董事会办公室 提交具体议案及其附件材料。提议人主体包括： （一）董事长； 第二章 议案的主要内容 1 （二）代表十分之一以上表决权的股东； （三）三分之一以上董事； （四）审计与风控委员会； （五）二分之一以上独立董事； （六）总经理； （七）《公司章程》规定的其他情形。 第四条 提交董事会的议案应当属于董事会职权范围，具 体以《公司章程》和《董事会议事规则》等相关规定为准。 第五条 提交董事会的议案内容应做到目标明确， ...

内部审计工作规定 第一章 总 则 第一条 为加强和规范中国医药健康产业股份有限公司 （以下简称"公司"）内部审计工作，完善公司内部审计制 度，提升内部审计工作质量，促进公司依法合规经营，根据 《中华人民共和国审计法》及其《实施条例》《审计署关于 内部审计工作的规定》《上海证券交易所上市公司自律监管 指引第 1 号——规范运作》以及《中国医药健康产业股份有 限公司章程》等有关规定和要求，制定本规定。 第二条 公司内部审计工作坚持以习近平新时代中国特 色社会主义思想为指导，以习近平总书记关于审计工作重要 指示批示精神为根本遵循，坚决贯彻党中央"应审尽审、凡 审必严、严肃问责"的指导思想和构建"集中统一、全面覆 盖、权威高效"审计监督体系的总体要求，坚持公司党委对 内部审计工作的全面领导，立足新发展阶段，贯彻新发展理 念，构建新发展格局，以推动高质量发展为主题，紧密围绕 党中央重大决策部署和公司发展战略落实情况，全面履行审 计监督职责，拓展审计监督广度和深度，突出对重点单位、 重大资金和重要项目的审计监督，揭示经营管理中的重大风 险隐患，促进公司做强做优做大、实现高质量发展。 中国医药健康产业股份有限公司 第九条 ...

证券代码：600056 证券简称：中国医药 公告编号：临2025-088号 中国医药健康产业股份有限公司 第九届董事会第 33 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 中国医药健康产业股份有限公司董事会 (三)本次会议应参加会议董事8名，实际参加会议董事8名。 (四)本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议为 有效决议。 二、会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于修订<内部审计工作规定>的议案》。 制度全文请详见上海证券交易所网站（www.sse.com.cn）。 表决结果：同意 8 票；反对 0 票；弃权 0 票。 （二）审议通过了《关于制定<董事会议案管理办法>的议案》。 制度全文请详见上海证券交易所网站（www.sse.com.cn）。 表决结果：同意 8 票；反对 0 票；弃权 0 票。 特此公告。 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第33次 会议（以下简称"本次会议"）于2025年11月24日以 ...